Why the study?
Does IVIG treatment improve clinical outcomes in an infant with HPeV1-associated dilated cardiomyopathy?
Does IVIG treatment improve clinical outcomes in an infant with HPeV1-associated dilated cardiomyopathy?
IVIG treatment may be effective for severe viral myocarditis or dilated cardiomyopathy caused by prevalent viruses like HPeV1 due to high neutralizing antibody titers in the preparation.
IVIG may aid recovery in HPeV1 cardiomyopathy; leaves open efficacy in controlled trials before practice change.
Human parechoviruses (HPeVs) are closely related to human enteroviruses and exhibit many similarities in disease spectrum and symptoms. HPeV1 is most commonly associated with mild disease, but rare associations with severe disease such as myocarditis have been reported. Currently, no treatment is available for severe HPeV infections. In this case report we describe an infant with a severe, dilated cardiomyopathy in whom HPeV1 was revealed to be the only identifiable cause. The infant was treated with intravenous immunoglobulins (IVIGs) and recovered completely. In vivo blood samples revealed a high HPeV1 antibody titer after treatment with IVIGs. In vitro IVIGs contained high titers of neutralizing antibodies against HPeV1. Our hypothesis is that patients with myocarditis caused by viruses with a high prevalence in the population and hence high antibody titers in IVIGs are likely to benefit from treatment with IVIGs. More research combining virological and clinical data is needed to see whether this hypothesis is true.
No takes yet. Share an insight, caveat, or question.
Wildenbeest et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: